Clinical trial · Interventional
PPI Therapy Impact on GERD After Sleeve Gastrectomy
Impact of Treatment With Protonic Pump Inhibitors After Laparoscopic Sleeve Gastrectomy on Gastro-esophageal Reflux Disease Symptoms: Pilot Study
NCT04400136CI-TRIAL-00045225unknownEarly Phase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The trial would to try to establish: * The best post-operative PPI prescription protocol after Sleeve Gastrectomy * The impact of PPI therapy on postoperative peptic diseases (erosive gastropathies, ulcers, duodenitis, esophagitis and/or Barrett) * The impact of PPI therapy on post-operative GERD symptoms (assessed with the use of two standard tests: MRGE-HRQL and GERDQ
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bariatric Surgery Candidate | — | UNRESOLVED | — |
| Barrett Esophagus | — | UNRESOLVED | — |
| Gastro Esophageal Reflux | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Lansoprazole oral tablets 30 mg | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- NO_INTERVENTION
- label
- GROUP A - no PPI
- description
- no PPI treatment (control group)
- type
- EXPERIMENTAL
- label
- GROUP B PPI 1/day for 6 months
- description
- (standard dose-long term): Lansoprazole oral tablets 30 mg once daily (before breakfast on an empty stomach) for 6 months
- interventionNames
- Drug: Lansoprazole oral tablets 30 mg
- type
- EXPERIMENTAL
- label
- GROUP C PPI 1/day for 3 months
- description
- (standard dose-short term): Lansoprazole oral tablets 30 mg once daily (before breakfast on an empty stomach) for 3 months
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Patients candidates for primary SG * Patients adhering to the follow-up protocol * Age between 18 and 65 years * No BMI limits Exclusion Criteria: * Gastric and/or esophageal diseases (routine preoperative endoscopy) * Patients candidate for revisional bariatric surgery * Chronic preoperative PPI therapy * Using of PPI treatment for postoperative complications * Conversion to open surgery * Patients allergic to PPI * Patients undergoing concomitant surgery * Patients with hiatal hernia undergoing concomitant cruroplasty
References
Publications (0)
Data not yet available
No reference posted for this study.